We’re pleased to announce the publication of the AVERectal study, a significant clinical research article led by Dr. Ali Shamseddine and his team at the
Call for Applications Grant Application Template 🚀 Oncodistinct Biannual Grant – €20,000 To support academic clinical research within our network : Funding Amount: €20,000 Application Deadline: June 1,
When : Thursday 19 and Friday 20 June 2025
Where : The Bank of Cyprus Oncology Centre in Nicosia (Cyprus).
For more details, please send an e-mail to oncodistinct@hubruxelles.be
📢 Francesco Sclafani and Ali Shamseddine from the Oncodistinct Network, had the opportunity to present Oncodistinct trials (REGINA & AVERECTAL) at the last ESMO GI 2024 in Munich, Germany
Oncodistinct Network achieved important milestones for SHAPERS and COPERNIC studies
Jérémy Blanc presented survival data results from AURA trial: Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004) at ASCO 2024 in Chicago, USA
We are pleased to announce that the next Oncodistinct Meeting will take place on Thursday 17th & Friday 18th October 2024 at the Institut Paoli-Calmettes in Marseille, France. Please save the date !
First results from our BRAINSTORM 🧠Program was presented by our our executive Officer Nuria Kotecki at AACR24 and EBCC14.
Meeting of the Oncodistinct network on January 25 and 26, 2024 at the Institut Jules Bordet in Brussels.
ONCODISTINCT. Accelerating Oncology drug Development and Innovative strategies in Clinical Trials
© Oncodictinct 2024 – Privacy policy
